OptoVAX - About the company
OptoVAX is an unfunded company based in Germany. It operates as a Developer of live attenuated vaccines to prevent intestinal parasitic infections. OptoVAX has not raised any funding yet. The company has 15 active competitors, including 4 funded and 2 that have exited. Its top competitors include companies like La Jolla Pharmaceutical, Hatchtech and Astra.
Company Details
Developer of live attenuated vaccines to prevent intestinal parasitic infections. This technology utilizes an attenuation procedure to treat parasite eggs, ensuring safety and consistency in vaccine production. The process employs a timing mechanism to arrest parasite development within host tissues, which facilitates an immune response while preventing chronic infection. This approach provides an alternative to conventional anthelmintic treatments for managing parasitic diseases in humans and animals.
Key Metrics
Sign up to download OptoVAX's company profile
OptoVAX's funding and investors
OptoVAX has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
OptoVAX's Competitors and alternates
Top competitors of OptoVAX include La Jolla Pharmaceutical, Hatchtech and Astra. Here is the list of Top 10 competitors of OptoVAX, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | La Jolla Pharmaceutical 1989, San Diego (United States), Acquired | Innovating critical care and infectious disease therapies for global health | - | 54/100 | |
2nd | Developer of proprietary head lice drugs | $31.4M | 52/100 | ||
3rd |  Astra 2019, Villigen (Switzerland), Seed | Developer of small molecule anti-parasitic drugs using structural data | $9.77M | 42/100 | |
4th | Acetylon 2008, Boston (United States), Acqui-Hired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $138M | 41/100 | |
5th | Topaz Pharmaceuticals 2005, Horsham (United States), Acquired | Pediatric medicines for treatment of head lice | $20.8M | 35/100 | |
6th | Abgenics Life Sciences 2010, Pune (India), Funding Raised | Developer of drugs for intestinal worm infections using probiotic strains of the bacterium Lactobacillus | - | 34/100 | |
7th |  Zero Point Five Therapeutics 2018, Baltimore (United States), Series A | Developer of therapeutics for infectious diseases | $11.5M | - | 33/100 |
8th |  KAINOMYX 2019, San Francisco (United States), Seed | Developer of therapeutic solutions for treating malaria and other parasitic diseases | $13.5M | 32/100 | |
9th |  TYDOCK PHARMA 2006, Modena (Italy), Funding Raised | Developer of chemotherapeutic drugs for parasitic diseases | - | 29/100 | |
10th |  NemaGen 2019, Cranbury (United States), Funding Raised | Developer of therapies for allergic inflammation and mast cell-related diseases | - | 28/100 | |
18th | Developer of live attenuated vaccines to prevent intestinal parasitic infections | - | - | - |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on OptoVAX's competitors? Click here to see the top ones
OptoVAX's Investments and acquisitions
OptoVAX has made no investments or acquisitions yet.
Reports related to OptoVAX
Here is the latest report on OptoVAX's sector:
Are you a Founder ?
FAQs about OptoVAX
Explore our recently published companies
- VerdeAds - United Arab Emirates based, 2023 founded, Unfunded company
- Superior Group - Basildon based, 2010 founded, Unfunded company
- Bibera Group - United States based, 2018 founded, Unfunded company
- Socialmood - Spain based, 2008 founded, Unfunded company
- W7 Seven - Russia based, Unfunded company
- Twin Peaks - Portland based, 2022 founded, Unfunded company
